Jingfeng Pharmacuetical ——not only providing quality products

Company Profile

Professional pharmaceutical manufacturer

Focus on prescription

drug

Outstanding for marketing and

product competence

Currently composing full heath industry

layout

China based International

enterprise

2

Contents

Chinese Medical Industry

Jing Feng History & Structure

Jing Feng Product and R&D

Jing Feng Market Size

and Strategy

3

Market Size in 2020 RMB 8 Trillion

Medical Device RMB 1.0 Trillion （13%）

Pharmaceutical RMB 2.4Trillion （30%）

Medical Service RMB 4.6 Trillion

（57%）

Chinese Booming Medical and Pharmaceutical Market

Reform brings opportunity, rapid upward trend with enormous fluctuation

Stable Growth

2 Growth Path for the Industry

CAGR 20%

Market Size in 2014 RMB 3 Trillion

Medical Service RMB 1.5 Trillion

（50%）

Pharmaceutical RMB 1.2Trillion（40%）

Medical Device RMB 0.3 Trillion（10%）

4

5

Medical DevicePharmaceutical

Medical Service

0.3 1.2 1.5

1.0

2.4

4.6

2014（RMB Trillion） 2020（RMB Trillion）

Rapid Growth in each Unit of Chinese Medical and Pharmaceutical Market

In the future 6 years, pharmaceutical unit is expected to

grow with CGAR of 12%. Meanwhile, the medical device

and service units will have even stronger growth.

CAGR 22%

CAGR 12%

CAGR 21%

12%

New Trends in Chinese Medical and Pharmaceutical Market

Big Data

Gene Sequencing & Precise Medicine

Innovative Equipment

Wearable Device

mHealth

-Platformization, Mobile Internet, Big data

Chinese Medical Industry

Jing Feng Product and R&D

Jing Feng History & Structure Jing Feng Market Size

and Strategy

7

目录Contents

Dec, 2009

• Former founder and chairman of Guizhou

Yibai Pharmaceutical Mr. Ye Xiangwu

acquired Yibai’s subsidiary Baijiayi

Pharmaceutical

2010-1-23

• Establishment of

Shanghai Jingfeng

2014-11-26

Approve listed by China

Securities Regulatory

Commission

000908.SZ

Jing Feng’s History

2010 Revenue：RMB 0.42 Billion

2014 Revenue：RMB 2.26 Billion

Founder Team

Jingfeng Parmacuetical·72 Shareholders

Jingfen【Fortify Foundation· Survival and Development】Management Conference——2015

10

In the past 5 years, Jingfeng’s revenue has grown from RMB 0.37 billion to almost 2 billion, with a CAGR of 39.6%, far more than the average.

Jing Feng's Revenue Growth

0

50,000

100,000

150,000

200,000

250,000

2010 2011 2012 2013 2014

Revene Growth Trend of Jingfeng（Unit：10k RMB）

Hainan Jingrui

Guizhou Jingcheng

Jingfeng Injections

Shanghai Jingfeng

Total

In the past 5 years, Jingfeng’s net profit has grown from RMB 20 million to over RMB 240 million, with a CAGR of 61.6%

Jing Feng's Profit Growth

-5,000

0

5,000

10,000

15,000

20,000

25,000

30,000

2010 2011 2012 2013 2014

Net Profit Growth Trend of Jing Feng (Unit: 10k RMB)

Hainan Jingrui

Guizhou Jingcheng

Jingfeng Injection

Shanghai Jingfeng

Total

11

TCM extraction

and preparation

Production Base

3 GMP

Production Line

Injection

Production Base

5 GMP

Production Line

Biologics

Production Base

4 GMP

Production Line

Jing Feng Pharmaceutical

Shanghai

Jing Feng

Guizhou

Jing Feng

Guizhou

Jing Chen

Hainan

Jin Rui

Dalian

Jin Gang

Haiman

Hui Ju

Hangzhou

Jia Wei

Jinsha

Hospital

Chemical Generics

Production Base

4 GMP

Production Line

APIs

Production Base

6 production lines qualified by CFDA,FDA,EDQM

1 production line MOA

Liposome

Production Base

3 GMP

Production Line

Sodium Hyaluronate Series

Production Base

Medical Device production line

Jing Feng Subsidiaries Structure

12

Jingfeng strategy into Medical care test ground

Shanghai J ingfeng Pharmaceut ica l （ B i o l o g i c s P r o d u c t i o n B a s e ）

A c q u i r e d b y J i n g f e n g i n 2 0 0 9 ， h e a d o f f i c e l o c a t e d o n T i m e S q u a r e i n P u d o n g D i s t r i c t a n d f a c t o r y i n

L u o d i a n To w n , B a o s h a n D i s t r i c t , S h a n g h a i . I t c o v e r s a n a r e a o v e r 7 8 0 0 0 m 2 w i t h 4 G M P p r o d u c t i o n

l i n e s a n d 8 7 9 e m p l o y e e s ( i n c l u d i n g 6 0 0 p e o p l e f r o m s a l e s a n d m a r k e t i n g d e p a r t m e n t ) . M a i n p r o d u c t s

a r e S o d i u m H y a l u r o n a t e I n j e c t i o n , A n a l g e s i c A c t i v e t i n c t u r e , A P I a n d e t c . .

Guizhou Jingfeng pharmaceutical （ I n j e c t i o n P r o d u c t i o n B a s e ）

A c q u i r e d b y J i n g f e n g i n 2 0 1 0 , l o c a t e d o n N o . 1 5 8 , G a o x i n R d , Wu d a n g d i s t r i c t , G u i y a n g c i t y,

c o v e r e d n e a r l y a 2 0 0 0 0 m 2 a r e a w i t h 5 G M P p r o d u c t i o n l i n e s a n d 4 8 3 e m p l o y e e s . M a i n p r o d u c t s a r e

S h e n x i o n g G l u c o s e I n j e c t i o n , L e m a i P i l l , R o o s t e r P i l l , N a l o x o n e H y d r o c h l o r i d e I n j e c t i o n a n d e t c . .

Guizhou Jingchen pharmaceutical （ P r o d u c t i o n B a s e ）

A c q u i r e d b y J i n g f e n g i n 2 0 1 3 , p r o d u c t i o n b a s e l o c a t e d i n X i u w e n p h a r m a c e u t i c a l i n d u s t r i a l p a r k

G u i y a n g , c o v e r e d a 1 0 0 , 0 0 0 m 2 a r e a w i t h 3 G M P p r o d u c t i o n l i n e s a n d 3 0 5 e m p l o y e e s . M a i n p r o d u c t s

a r e X i n n a o n i n g c a p s u l e , D i t o n g c a p s u l e , F u p i n g c a p s u l e , X i a o y a n L i d a n c a p s u l e , E r t o n g h u i c h u n

g r a n u l e s a n d e t c . .

Hainan Jinrui pharmaceutical （ C h e m i c a l G e n e r i c s P r o d u c t i o n B a s e ）

A c q u i r e d b y J i n g f e n g i n 2 0 1 4 , p r o d u c t i o n b a s e i s i n t h e f r e e t r a d e z o n e H a i k o u C i t y. I t o w n s 4 G M P

p r o d u c t i o n l i n e s a n d 2 4 1 e m p l o y e e s . M a i n p r o d u c t s a r e I r i n o t e c a n H y d r o c h l o r i d e I n j e c t i o n ,

O x a l i p l a t i n f o r i n j e c t i o n , L o r n o x i c a m f o r i n j e c t i o n , I f o s f a m i d e f o r i n j e c t i o n a n d e t c . .

Dalian Holley Kingkong Pharmaceutical （ L i p o s o m e P r o d u c t i o n B a s e ）

A c q u i r e d b y J i n g f e n g i n F e b 2 0 1 5 , t h e p r o d u c t i o n b a s e i s l o c a t e d i n D a l i a n C i t y L i a o n i n g P r o v i n c e

c o v e r e d a 4 0 , 0 0 0 m 2 a r e a w i t h 3 G M P p r o d u c t i o n l i n e s a n d 4 7 0 e m p l o y e e s . M a i n p r o d u c t s a r e E l e m e n e

i n j e c t i o n a n d o r a l l i q u i d , X u e k a n g o r a l l i q u i d , J i n g l i n g o r a l l i q u i d a n d e t c . .

Wisdom Pharmaceutical （ A P I s P r o d u c t i o n B a s e ）

A c q u i r e d s h a r e b y J i n g f e n g i n 2 0 1 2 . T h e r e a r e t h r e e f a c t o r i e s w h i c h c o v e r e d a r e a s o f 3 4 6 3 2

m 2 , 5 7 2 7 6 m 2 a n d 3 3 3 0 0 m 2 . M a i n p r o d u c t s a r e A P I , P h a r m a c e u t i c a l I n t e r m e d i a t e s a n d e t c . . T h e

c o m p a n y i s c e r t i f i c a t e d I S O 9 0 0 1 : 2 0 0 0 R & D m a n a g e m e n t o f q u a l i f i c a t i o n s y s t e m b y B r i t i s h N o r w a y

c l a s s i f i c a t i o n s o c i e t y . S i x p r o d u c t i o n l i n e s a r e q u a l i f i e d b y C F D A , F D A , E D Q M s t a n d a r d a n d o n e

l i n e c e r t i f i c a t e d b y C h i n e s e v e t e r i n a r y d r u g q u a l i f i c a t i o n m a n a g e m e n t s y s t e m .

Hangzhou Gallop Biological Products （ S o d i u m H y a l u r o n a t e S e r i e s P r o d u c t i o n B a s e ）

A c q u i r e d s h a r e s b y J i n g f e n g i n 2 0 1 4 , l o c a t e d i n X i h u d i s t r i c t , H a n g z h o u , Z h e j i a n g p r o v i n c e . I t

o w n s 1 3 1 e m p l o y e e s a n d m e d i c a l d e v i c e p r o d u c t i o n l i n e s q u a l i f i e d b y I S O 9 0 0 1 , I S O 1 3 4 8 5 a n d C E .

T h e a n n u a l p r o d u c t i o n i s o v e r 1 . 8 m i l l i o n u n i t s . M a i n p r o d u c t s a r e J o i n t f u n c t i o n i m p r o v i n g a g e n t ,

A n t i - a d h e s i o n b a r r i e r a g e n t , Vi s c o - e l a s t i c p r o t e c t i v e a g e n t , S o d i u m h y a l u r o n a t e a n d I n v i t r o

d i a g n o s t i c r e a g e n t s .

Chengdu Jinsha Hospital A c q u i r e d b y J i n g f e n g i n 2 0 1 4 ， a l s o k n o w a s C h e n g d u w o m e n a n d c h i l d r e n ’s h o s p i t a l . I t i s g r a d e 2 A

h o s p i t a l a u t h o r i z e d b y n a t i o n a l h e a l t h a d m i n i s t r a t i o n . I t i s a n o n - p r o f i t h o s p i t a l , m e m b e r o f 1 2 0

e m e r g e n c y n e t w o r k , d e s i g n a t e d d i s t r i c t h e a l t h i n s u r a n c e u n i t a n d d e s i g n a t e d c h i l d r e n ’s

h o s p i t a l i z a t i o n f u n d h o s p i t a l i n C h e n g d u . I t i s t h e f i r s t b e n e f a c t i o n p e o p l e h o s p i t a l i n Q i n g y a n g

d i s t r i c t a s w e l l .

Jing Feng Product and R&D

Jing Feng History & Structure

Chinese Medical Industry

Jing Feng Market Size

and Strategy

21

Contents

Jing Feng's Product Portfolio • Jingfeng manage to design products with large market as key products, featured drugs as

main product and supplement with generic drugs

Shenxiong Elemene Injection

Elemene Oral Liquid

Sodium Hyaluronate Injection

Xinnaoning

Xiaoer Huichun, Peimei etc.

Fuping Capsule

Ditong Capsule

Active tincture

Lemai Pill

Supplementary products

The generic drugs already on the market and other products in total of 20

Reserve Products

• Astragaloside IV • HA1、HA2 • AAFP • JZB01、02、03、04

• 8 featured drugs • 30 generic drugs • Featured devices

22

Jing Feng's Intellectual Property

214 Registered Trademarks

6 Assigned Patents

105 Patents for Invention

131 Patents Authorized

239 Patent Applications

23

Jingfeng R & D system—R & D Platform and Main Cooperation Companies

24

Shanghai institute of materia

medica, Chinese academy of

sciences

Jinan university

Peking union medical college

hospital

The Fudan University school of medicine

School of biotechnology,

Jiangnan university

Shanghai university of traditional

Chinese medicine

Guiyang medical university

Guiyang college of traditional

Chinese medicine

The second military medical

university

East China university of Science and technology

Sichuan university State key

laboratory of biology

• National market access network

• National drug administration

network

• Provincial market access network

3 Networks

• National drug administration

expert base

• National directory expert base

2 Expert Base

Jingfeng Technology

Platform

Liposome Platform

Jingfeng Acquiring

Plan

Class 1.1 new drug 1-3 products

Class 3.1 (antineoplastic) drug 2-3 products

Class 3.1 generic drug 5-8 products

Biological drug 2-4 products

Pronucleus and eukaryon systems

Asymmetric synthesis platform

Jingfeng R & D Platform and Division

25

R&D team R&D Coverage

• Jingfeng technology center

• Jingze Biotech

• Jingrui Pharmaceutical

• Wisdom Pharmaceutical

• Shanghai Kexin Pharmaceutical

• Project overall planning, big projects R&D

• Biologic generic drug and biologic ingredients

• Chemical generic drug

• Chemical APIs and intermediates

• Biologic innovative drugs

Shanghai Jingze Biotech-Development Positioning

Jingze

Biotech

Chemical drug

Cooperative

Development

Platform Biomaterial

Product

Development

Platform

Innovative

Pharmaceutical

Preparation

Development

Platform Biotechnology

Service

Platform

Antibiotic

drug

Development

Platform

Protein drug

Development

Platform

Research Team • R&D team of almost 70 people in chemistry, biology and preparations technology

• Bring several Chinese professional talents into the team

Sun Haisheng, vice president in Jinghua Pharmaceutical Group Co., Ltd; former director of Yangzi River Pharmaceutical Group Medical Research Laboratory

Gan Li, former Shanghai medical researcher in Chinese Academy of Sciences; one year working experience in CFDA CDE.

Zhang Qingyi, over 20 years working experience in 3SBIO and other companies in the industry; rich experience in bio-pharmaceuticals and international register.

Production & Research Cooperation Platform

• Engage academician of Chinese Academy of Sciences Fu Xiaobin as chief scientist

• Engage national pharmaceutical assessment lead Xi Yanfei as counselor to fully support R&D

• Establish "Tissue repair materials engineering technology innovation center" with China West Normal University

Annual investment 10 million from Xihua University to build experimental lab facility occupied 3000 m2; 4 doctors and 8 assist researchers are fully supporting innovation project development of Jingze

Shanghai Jingze Biotech-Research Team

Shanghai Jingze Biotech-Products under Research

Biopharmaceutical

JZB02 PDGF-BB

JZB03 PEG30-G-CSF

JZB04 EGFR

JZB06 FSH

JZB01 BNP

JZB05-I VEGF-Trap AMD

JZB05-II VEGF-Trap Oncology

Medical Devices

JZM01

JZM02

JZM03

JZM04 NDAJZM05 phaseⅢ

JZM06phaseⅡ

CRO phaseⅠ

JZS01 Avastin IND

JZS02 Humira CMC & preclinical

2022 2023 2024

Collagen Dura Substitute Membrane

Collagen Wound Membrane

2015 2016 2017 2018 2019 2020

bFGF/collagen complex

PDGF/collagen/HA complex

HA Aesthetic Dermal Filler for Wrinkle and Folds

Lidocaine/HA Aesthetic Dermal Filler for

Wrinkle and Folds

2021

60 patent application， 20 authorized ， 12 transfered

9 new drug certificate，4 Clinical Trial Authorization， 3 CFDA NDA

Project Co-operation：SIMM Nano Drug & TDDS Lab

Nanotech increase of indissolvable drug oral absorption

Drug nano release system of anti-tumor metastasis and reversal of drug resistance

1

New drug dosage form and preparation R&D

2

3

4

Nucleinic acid drug nonviral vector and delivery system

Adv Mater 4 articles

Nat Med 1 articles

Adv Drug Deliv Rev 1 articles

ACS Nano 2 articles

JACS 1 articles

Adv Funct Mater 8 articles

Small 4 articles

J Control Release 10 articles

Biomaterials 22 articles

SCI 120 articles

，IF > 5, > 60%

“Hot paper” “Top 10 paper” “Most accessed articles”

Yaping Li： Research team leader, PhD supervisor, Director of pharmaceutic preparation lab,973 program chief scientist, Distinguished Young Scholars, Chinese Academy of Science Hundred-Talent Program

Wisdom Pharmaceutical Co., Ltd

Large R&D and industrialization base, National High-tech

Enterprises, Nantong Engineering Research Center for Chiral

drugs, Provincial Post-doctoral Workstation, Academician

Workstation, Jiangsu Chiral Synthesis of Chemical Engineering

Research Center, Provincial Engineering Research Center, and

Jiangsu Innovative Enterprises

Xiaolong Qiu：Wisdom Pharmaceutical R&D vice president，Doctor of Shanghai Institute of Organic Chemistry CAS, post-doctor from University of California, Irvine, breast cancer R&D project researcher of US Department of Defense in 2006-2010， has great achievement in fluorine chemistry

Wisdom owns a professional R&D team of 50 person, including 4 PhDs and 10 masters

Benazepril

Tirofiban HCl

Alogliptin

Clinofibrate

Linagliptin

Fasudil HCl

Dronedarone

Fosaprepitant

Aprepitant

Moxifloxacin

Lamivudine

Entecavir

Bendamustine

Fulvestrant

Gemcitabine

S-Omeprazole

Flurbiprofen

Flupirtine Maleate

Flurbiprofen axetil

Anti-cancer

Blood and Blood Vessel

Independent

GMP Plants

Intermediate Plants

1 unit, scale (10L,20L,50L)

Commercial

IND/NDA Reg 1 unit, scale (100L, 200L)

2 unit, scale (500L- 3000L)

3 unit, scale (50L- 5000L)

7 GMP Lines

Anti-cancer APIs 2 unit, 1×500L/100L, 1×200L/50L

are under installation

Two Plants (total 7 workshops) are running:

The 3rd new Plant is available:

Commercial

2 unit, scale (2000L, 5000L)

3 unit, 1×1500L/200L, 1×3000L/500L

are under installation

Independent Anti-cancer APIs

Wisdom Pharmaceutical Co., Ltd—Production Workshops and Facilities

Hainna Jinrui Pharmaceutical Co., Ltd

R&D Mode：Combination of Independent and Joint R&D Mode

Rely on enterprise R&D center cooperation with 12 universities and

institutions to complete project linkage, build technology innovation and result

transform systems

Core Competence and Technology Platform

Preparation transform application, Project management and linkage capability,

enterprise R&D center craft prescription,

crystal form particle size research etc.

Research Team

Team size of 40 person，1PhD，1

master，19 Bachelors，9 person withhold

above senior professional titles

Patents

68 patent applications，national patents

for invention authorized，8 patent acceptance notices

Hainan Jinrui

Dedicate in antineoplastic, diabetes, CVD and other chronic diseases drugs research and development

-71 projects of new drugs established，48 new varieties registered and declared, 21 new drug production licenses and 3

clinical trial permissions

Chinese Medical Industry

Jing Feng History & Structure

Jing Feng Product and R&D

Jing Feng Market Size and

Strategy

33

Contents

34

6

Stable

Sales

Team and

Powerful

Execution

2

Market

Access

Capability

1

Market

Network

Basis

3

Market Trend

Judgement

and

Competitive

Marketing

Model

4

Professional

Academic

and

Promotion

Ability

5

Elaborate

Effective

Information

managemen

t System

Jing Feng’s Market Core Competence

Jing Feng's Market Scale

Sales team of 1400 persons

Marketing access team

of near 30 persons

Cover 7000 hospitals

1900 business

channels

Over 3200

cooperators

100,000 doctors

3 million patients

High Medicare marketing

share of Jingfeng main

products:

Shenxiong Glucose Injection：

27 Medicare provinces ( city

Medicare in Hebei and

Shandong), 4 non Medicare

provinces (Beijing, Shanghai,

Hunan and Xizang)

HA：National Medicare Grade B,

Medicare No.1046

Xinnaoning：National Medicare,

Medicare No.400

Elemene ( Injection and Oral

liquid) : National Medicare,

Medicare No.475

35

36

Jing Feng’s Academic

Events

2014 Chinese Hospital Association

Hospital Management Seminar

Jing Feng’s Market Leadership——Professional Academic Events

Decode Huax Hospital Director

Symposium

America Mayo Clinic Conference

Tianjing Base Hospital Symposium

Shanghai Mayo Clinic Conference

Rainbow Project Hangzhou Station

CMOH Prevention and Control System of Chronic Diseases

Symposium

Meeting Jingfeng Guizhou

Conference

CMA Magazine Manuscripts Review

Expert Training

Jing Feng’s Market Leadership——Elaborate Effective IMS Jing Feng’s CRM system core objectives：

Data Path Control

Client Resource Integration

Marketing Efficiency Improve

Input-Output Rationalization

Business Channels

Agency Clients

Terminal Clients

VIP Clients

商务队伍 招商队伍 自营队伍

一级商业 二级商业

挂靠代理 资质代理

外包代理 兼职代表

Others

Hospital Department Doctor

KDM

KOL PR

市场队伍

Clients

客户 产品 代表

营销效能分析

终端纯 销贡献

营销资源投入

客户拜访与协访

学术POA市场活动

日常销售管理SOP

代理招商与招募

终端开发与促量

政府事务与VIP维护

客户资源增长计划

市场活动方案计划

终端进货消化计划

销售活动目标计划

费用资源投入预算

目标终端销售潜力

目标区域销售潜力

目标招商覆盖潜力

营销网络配送能力

商业销售指标

招商销售指标

自营销售指标

Pharma Production

Tier Ι Distributor

Target Hospital

Target Doctor

医院潜力 医院进销存

医生潜力 医生处方量

Tier Ⅱ Distributor

订发回 信用应收

一级流向 商业进销存

二级流向跨区窜货

Budget Plan Accrual Usage Audit

Input-output analysis 考核数据

费用政策

年度销售 计划指标

发货回款

年度费用预算总额

公司月度费用预算

区域月度 费用预算

销售指标计划

客户开发计划

销售活动计划

区域月度营运计划

商业/代理返利

代理佣金费用

一线销售费用

代表销售奖金

活动总 结说明

销售行 为填报

有效数 据证明

报销申请

报销审批

财务审核

37

A Chinese medicine enterprise cluster 1. Group over 10 enterprises 2. Full industry chains combination including

Chinese medicine preparation, cancer adjuvant therapy, planting of traditional Chinese medicinal materials, Chinese herbal medicine, health care products and etc.

3. Integration of R & D, production, sale and service.

4. Overall arrangement of both international and domestic

5. Goal on 2020 is over 6 to 8 billions

1.Group over 10 enterprises 2.Combination of medical instruments, diagnosis and treatment instruments 1.20000 sickbeds in total

2.Cover regional medical groups and national special hospitals chain 3.Focus on special hospital and support 4.Integration of training, learning, clinic and R & D 5.Integration of cooperated with both domestic and international 6.Combination of rentability and non-profit 7.Combination of stock holding and

Medical treatment & health enterprise cluster

Medical instruments enterprise cluster

B Biochemical medicine enterprise cluster

1.Group over 10 enterprises 2.Full industry chains combination including chemical agent & ingredients, injection, biological drug and etc.

Jingfeng’s Developing Strategy

38

3. Integration of R & D, production, sale and service. 4. Overall arrangement of both international and domestic 5. Goal on 2020 is over 6 to 8 billions

3.Mainly focused on med-high production 4.Overall arrangement of both international and domestic 5. Integration of R & D, production, sale and service. 6. Goal on 2020 is over 2 to 3 billion

Innovative Orientated

Biological & Innovative

Drugs • Jingze Series

• Exclusive innovation Drugs

• Featured first generic drug

Innovative Medical

Device • Cardiovascular

• Rehabilitation

• Surgery

• Innovative Diagnose

Equipment

• Biological Material

• Drug and device

combination

• Wearable Device

New Dosage Form and Technique • Nano-liposomes • Sustained Release

Internationalization • ANDA

• Ordinary generic drugs

• More APIs（DMF）

Jing Feng's Innovative Orientated Strategy

Gene Sequencing（NGS） • Heredity

• Reproduction

• Pathopoiesia

• Precise diagnose

• Screening

Immunotherapy • TCR

• CAR-T

• Immune checkpoint monoclonal

antibody (PD-1、PDL1)

Precise

Medical

39

Jing Feng Group Goal—Leading Company of the Big Health Industry

Internation

alization

Hospitals

Bio-chemicals

Existing Drug

and New Product

Direction

4 Clusters Domestic and oversea joint operation

（Internet) Healthcare Service joint operation

Chinese

patent

drug

Injections

Chemical

Drugs Biological

Drugs

Regional

Medical

（Sichuan

）

Tumor

TCM

injection Department

trusteeship

Chronical Disease

Sub-health

mHealth Retirement

Industry

4 Key Capabilities:

Strategy, Talents, Management

and Capital

Food

Cosmetics

Chinese

Herb and

decoction

pieces

APIs

TCMs

Devices

Formula

granules

Regional

Medical

（Guizhou)

Chain

（ENT） Chain

(gynecology

and

obstetrics)

HA drug

and device

combination

series New technic

device series

Diagnose

Series Innovative

technology

(e.g. Gene

sequencing)

40

Shared

Resources

Adjust to Industry Revolution, Create Life Value

41

Government

Partners

• Wider ecological connection

• More open company resources

• More optimized working Path

• Stronger customer orientation

• More sublime working mission

Patients Healthy People

Chronic disease people

Terminal Agents

and Distributors

Suppliers

Associations,

Unions, etc.

Jingfeng Health

Schema

Key decision maker

Private hospitals

Public hospitals

(country level above)

Experts and Doctors

Health Service

Institution

Third party terminal, drugstores

Others

The Mass

MOH

CFDA

Statutory

health insurance

Local

government

41

THANKS

唯高，愈远 登峰，揽景。